Timothy Grass Pollen Allergen Extract (Grastek)
Defines medical necessity criteria, approval durations, continuation criteria, exclusions, dosing, contraindications, and product availability for Grastek (Timothy grass pollen sublingual tablet) across Commercial, HIM, and Medicaid lines of business.
Added step therapy bypass for IL HIM per IL HB 5395 (effective 2026-01-01 referenced in body; logged 3Q 2025 annual review).
Revised approval duration for Commercial line of business to 12 months or duration of request, whichever is less (noted in 2021 revisions).
Multiple annual reviews from 2021-2024 noted 'no significant changes' and references updated.